Effects of eprosartan on glomerular injury in rats with reduced renal mass

Mehul M Gandhi, Timothy W. Meyer, David P. Brooks

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The effects of the selective angiotensin AT1 receptor antagonist, eprosartan, were evaluated in experimental renal disease. Five-sixth nephrectomy in male Munich-Wistar rats led to the development of hypertension, proteinuria and remnant glomerulosclerosis. Administration of the AT1 receptor antagonist, eprosartan, for 4 weeks resulted in inhibition of angiotensin II activity as confirmed by a reduced blood pressure response to exogenous angiotensin II challenge. Compared to vehicle treatment, eprosartan normalized blood pressure, reduced proteinuria and limited remnant glomerulosclerosis. These data suggest that eprosartan may provide a new tool in the treatment of progressive renal disease.

Original languageEnglish (US)
Pages (from-to)89-94
Number of pages6
JournalPharmacology
Volume59
Issue number2
DOIs
StatePublished - Aug 1999
Externally publishedYes

Fingerprint

Kidney
Wounds and Injuries
Proteinuria
Angiotensin II
Blood Pressure
Angiotensin Type 1 Receptor
Angiotensin Receptor Antagonists
Nephrectomy
Wistar Rats
Hypertension
eprosartan

Keywords

  • Angiotensin II
  • Glomerulosclerosis
  • Hypertension
  • Proteinuria

ASJC Scopus subject areas

  • Pharmacology

Cite this

Effects of eprosartan on glomerular injury in rats with reduced renal mass. / Gandhi, Mehul M; Meyer, Timothy W.; Brooks, David P.

In: Pharmacology, Vol. 59, No. 2, 08.1999, p. 89-94.

Research output: Contribution to journalArticle

Gandhi, Mehul M ; Meyer, Timothy W. ; Brooks, David P. / Effects of eprosartan on glomerular injury in rats with reduced renal mass. In: Pharmacology. 1999 ; Vol. 59, No. 2. pp. 89-94.
@article{0d069e8be91a4d1bb88d2a1a895bf560,
title = "Effects of eprosartan on glomerular injury in rats with reduced renal mass",
abstract = "The effects of the selective angiotensin AT1 receptor antagonist, eprosartan, were evaluated in experimental renal disease. Five-sixth nephrectomy in male Munich-Wistar rats led to the development of hypertension, proteinuria and remnant glomerulosclerosis. Administration of the AT1 receptor antagonist, eprosartan, for 4 weeks resulted in inhibition of angiotensin II activity as confirmed by a reduced blood pressure response to exogenous angiotensin II challenge. Compared to vehicle treatment, eprosartan normalized blood pressure, reduced proteinuria and limited remnant glomerulosclerosis. These data suggest that eprosartan may provide a new tool in the treatment of progressive renal disease.",
keywords = "Angiotensin II, Glomerulosclerosis, Hypertension, Proteinuria",
author = "Gandhi, {Mehul M} and Meyer, {Timothy W.} and Brooks, {David P.}",
year = "1999",
month = "8",
doi = "10.1159/000028308",
language = "English (US)",
volume = "59",
pages = "89--94",
journal = "Pharmacology",
issn = "0031-7012",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Effects of eprosartan on glomerular injury in rats with reduced renal mass

AU - Gandhi, Mehul M

AU - Meyer, Timothy W.

AU - Brooks, David P.

PY - 1999/8

Y1 - 1999/8

N2 - The effects of the selective angiotensin AT1 receptor antagonist, eprosartan, were evaluated in experimental renal disease. Five-sixth nephrectomy in male Munich-Wistar rats led to the development of hypertension, proteinuria and remnant glomerulosclerosis. Administration of the AT1 receptor antagonist, eprosartan, for 4 weeks resulted in inhibition of angiotensin II activity as confirmed by a reduced blood pressure response to exogenous angiotensin II challenge. Compared to vehicle treatment, eprosartan normalized blood pressure, reduced proteinuria and limited remnant glomerulosclerosis. These data suggest that eprosartan may provide a new tool in the treatment of progressive renal disease.

AB - The effects of the selective angiotensin AT1 receptor antagonist, eprosartan, were evaluated in experimental renal disease. Five-sixth nephrectomy in male Munich-Wistar rats led to the development of hypertension, proteinuria and remnant glomerulosclerosis. Administration of the AT1 receptor antagonist, eprosartan, for 4 weeks resulted in inhibition of angiotensin II activity as confirmed by a reduced blood pressure response to exogenous angiotensin II challenge. Compared to vehicle treatment, eprosartan normalized blood pressure, reduced proteinuria and limited remnant glomerulosclerosis. These data suggest that eprosartan may provide a new tool in the treatment of progressive renal disease.

KW - Angiotensin II

KW - Glomerulosclerosis

KW - Hypertension

KW - Proteinuria

UR - http://www.scopus.com/inward/record.url?scp=0032765816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032765816&partnerID=8YFLogxK

U2 - 10.1159/000028308

DO - 10.1159/000028308

M3 - Article

C2 - 10450063

AN - SCOPUS:0032765816

VL - 59

SP - 89

EP - 94

JO - Pharmacology

JF - Pharmacology

SN - 0031-7012

IS - 2

ER -